Cello Health PLC AGM Statement (2801Y)
08 May 2019 - 4:00PM
UK Regulatory
TIDMCLL
RNS Number : 2801Y
Cello Health PLC
08 May 2019
FOR IMMEDIATE RELEASE 8 May 2019
Cello Health plc
("Cello" or the "Group")
AGM Statement
Cello Health plc (AIM: CLL), the global healthcare-focused
advisory Group, announces that at the Annual General Meeting to be
held later today Chairman Chris Jones will make the following
statement:
"The Group has had a very good start to the year. For the first
quarter, the Group has experienced good like-for-like net revenue
and headline profit before tax growth. We are also confident
regarding performance in the second quarter, and expect to report
robust headline profit before tax growth for the first half of the
year.
"At a segment operating level, Cello Health has had an excellent
first quarter. In particular, the performances in our consulting
businesses and in the US overall are notable. We expect the second
quarter to continue this trend.
"Cello Signal has also made a solid start to the year in line
with expectations.
"The Group's balance sheet remains strong, with better than
expected cash conversion so far in 2019, continuing the strong cash
conversion performance delivered in 2018. The Group continues to
assess suitable acquisitive growth opportunities in the US.
"The Board is therefore confident of achieving a successful full
year result in 2019, in line with expectations."
Enquiries:
Cello Health plc 020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Group Finance Director
Cenkos Securities plc 020 7397 8900
Mark Connelly/Harry Hargreaves
Buchanan
Mark Court 020 7466 5000
Jamie Hooper
Sophie Wills
About Cello Health plc
We are a global healthcare-focused advisory Group comprised of a
set of leading clinical, commercial advisory and digital delivery
capabilities. We currently service 24 of the top 25 pharmaceutical
clients globally as well as a wide range of biotech, diagnostics,
devices and other key non-healthcare clients.
We enable clients to differentiate their propositions and drive
brand success in ever more complex global markets. We deliver our
services through nearly 1,000 highly skilled professionals
utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in
the UK, USA, Germany and Asia, with hub offices in New York,
Philadelphia, London, Berlin, Edinburgh, Farnham and
Cheltenham.
For further information, please visit:
https://cellohealthplc.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGMEAKSXEELNEFF
(END) Dow Jones Newswires
May 08, 2019 02:00 ET (06:00 GMT)
Cello Health (LSE:CLL)
Historical Stock Chart
From May 2024 to Jun 2024
Cello Health (LSE:CLL)
Historical Stock Chart
From Jun 2023 to Jun 2024